Decitabine + FLAG-Ida + TBI conditioning regimen
Current understanding
An investigational pre-transplant conditioning regimen combining decitabine (a hypomethylating agent) with FLAG-Ida (fludarabine, cytarabine, idarubicin, G-CSF) plus total-body irradiation, given before allogeneic stem cell transplant in adults with high-risk myeloid malignancies (AML, MDS, CMML). A phase I/II trial (trial-early) is comparing decitabine + FLAG-Ida + TBI vs. FLAG-Ida + TBI alone, testing whether HMA augmentation of intensive chemo-radiation conditioning reduces relapse risk in this high-risk population.
Evidence log
- 2026-05-15 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse: cross-connection with ap-bp-mpn-bridging: Both address pre-allo-HSCT cytoreduction in high-risk myeloid disease; decitabine + FLAG-Ida + TBI represents an intensified conditioning approach distinct from chemo-sparing HMA + JAKi bridging strategies. (novelty: 3)
Open questions
Related
Contributing findings
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
15-may-2026
novelty 3
per-area 3
introduces